Niagen Bioscience, Inc. — Director's Dealing 2012

Sep 27, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC.OB)
CIK: 0001386570
Period of Report: 2012-08-28

Reporting Person: Jaksch Frank L Jr (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-08-28	Employee Stock Options (right to buy)	$0.64	A	250000	Acquired	2022-08-28	Common Stock (250000)	Direct

Footnotes

F1: Options vest 25% on August 28, 2013 with the remainder vesting 1/36th per month over three years thereafter. Options will be fully vested as of August 28, 2016.